UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August, 2015
Commission File Number: 001-36575
MACROCURE LTD.
(Translation of Registrant’s name into English)
25 Hasivim Street
Petach Tikva 4959383, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F X Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Contents
On August 19, 2015, MACROCURE LTD. (NASDAQ:MCUR) issued a press release providing an update on futility analysis for its Phase III Clinical Trial of CureXcell® in venous leg ulcers, a copy of which is furnished herewith as Exhibit 1.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MACROCURE LTD. | |||
| (Registrant) | |||
| Date: August 19, 2015 | By: | /s/ Mark Page | |
| Name: | Mark Page | ||
| Title: | Chief Financial Officer | ||
EXHIBIT INDEX
| EXHIBIT NO. | DESCRIPTION |
| 1. | Press release of MACROCURE LTD. (NASDAQ:MCUR) providing an update on futility analysis for Phase III Clinical Trial of CureXcell® in venous leg ulcers, dated August 19, 2015. |
